OCUGEN, INC. Form 8-K (Dec. 22, 2020)

Summary

Current report on Form 8-K of Ocugen, Inc., dated December 22, 2020, filed under Items 8.01 and 9.01. It states that on December 22, 2020 the company issued a press release announcing a binding letter of intent with Bharat Biotech to co-develop Bharat’s COVID-19 vaccine candidate, COVAXIN, for the U.S. market. It describes the candidate as an advanced stage inactivated vaccine candidate currently in Phase III clinical trials. The press release is Exhibit 99.1. The signature block shows /s/ Shankar Musunuri, Chief Executive Officer and Chairman.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15
(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event
Reported): December 22, 2020

OCUGEN, INC.

(Exact Name of Registrant as Specified in
its Charter)

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

5 Great Valley Parkway, Suite 160

Malvern , Pennsylvania 19355

( 484 ) 328-4701

(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):

¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨ | Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨ | Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨

Item 8.01 Other Events

On December 22, 2020, Ocugen, Inc. (the
“ Company ”) issued a press release announcing that it has entered into a binding letter of intent
with Bharat Biotech (“ Bharat ”) to co-develop Bharat’s COVID-19 vaccine candidate,
COVAXIN™, an advanced stage whole-viron inactivated vaccine candidate currently in Phase III clinical trials, for the
U.S. market. A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

The following exhibit is being filed herewith:

(d) Exhibits

Exhibit No. | Document
99.1 | Press
 Release of Ocugen, Inc. dated December 22, 2020.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 22, 2020

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

2

File and source

File

SEC_OCGN_8-K_filed2020-12-22_0001104659-20-138385.htm

Size

26,560 bytes

SHA-256

42dd0f77890de731b58668b8e59a732636287f2f04b5aff20e3ead01e6c16fe7

Our copy

SEC_OCGN_8-K_filed2020-12-22_0001104659-20-138385.htm

Original

www.sec.gov